Sabrina Braham, MD, is a Design, Innovation, and Clinical Entrepreneurship Fellow at Stanford University’s Clinical Excellence Research Center and Assistant Professor of Pediatrics at Stanford University School of Medicine. She is a pediatrician, entrepreneur, and expert in digital health with a focus on creating high-value and equitable care for children by leveraging human-centered design and technology, and teaches and cares for patients at Stanford’s federally qualified health center, the Gardner Packard Children’s Health Clinic. A graduate of Georgetown University and the UC Davis School of Medicine, Dr. Braham completed Pediatrics residency at Lucile Packard Children's Hospital Stanford.
- Menlo Clinic > Pediatrics
Clinical Assistant Professor, Pediatrics - General Pediatrics
Boards, Advisory Committees, Professional Organizations
Clinical Advisor, Silicon Valley Innovations (2021 - Present)
Clinical Advisor, InSite Health (2020 - Present)
Clinical Advisor, Marker Learning (2020 - Present)
Founder, FeMD (2020 - Present)
Medical Education: University of California Davis School of Medicine (2006) CA
Residency: Lucile Packard Children's Hospital CA
Board Certification: American Board of Pediatrics, Pediatrics (2009)
Additional Clinical Info
Current Research and Scholarly Interests
Dr. Braham's work focuses on bending the arc of health innovation toward equity, value, and better population health. She is interested in the development, funding and implementation of innovative care models for child and family health.
Occlusive therapy in atopic dermatitis: Overview
JOURNAL OF DERMATOLOGICAL TREATMENT
2010; 21 (2): 62-72
Occlusive therapy, including both dry and wet ('wet-wrap therapy') offers a treatment option in atopic dermatitis (AD) which may be underutilized in clinical practice due to concerns about burdensome regimens and potential complications. This review examines current evidence for the use of occlusion in AD.Keyword and title searches in PubMed and EMBASE were used to examine data on the use of occlusive therapy in AD from January 1966 to February 2009.Eighteen studies were found examining the use of occlusive therapy in AD. Of the 14 studies examining wet-wrap therapy, five were randomized controlled trials. All wet-wrap therapy studies demonstrated efficacy in severe or acute, moderate and chronic AD. Of the four studies examining dry occlusive therapy, a single controlled study of dry occlusion does not support a benefit over conventional open therapy. Increased cutaneous bacterial counts or clinical infection were reported in all studies using dry occlusion and in four of 14 studies utilizing wet-wrapping techniques.Available data are encouraging, though limited by the lack of adequate study controls and standardized designs. More controlled trials are indicated.
View details for DOI 10.3109/09546630902911854
View details for Web of Science ID 000274877000002
View details for PubMedID 19444691